The Ryvu Therapeutics project for RVU120 has a recommendation for PLN 62.27 million in funding from ABM

The Ryvu Therapeutics project “Performance of a Phase II, Multicenter, Open-label Clinical Study (RIVER-81) to evaluate the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior venetoclax plus venetoclax therapy hypomethylating” was placed on the ranking list of projects recommended for co-financing under the competition for the development of targeted or personalized medicine based on medicinal products based on nucleic acids and small molecule compounds of the Medical Research Agency (ABM). The total net value of the project is PLN 133,915,538.7, while the recommended co-financing value is PLN 62,268,848.90.

The planned duration of the project has been set at 48 months. The project received the highest number of ranking points among all submitted applications.


The aim of the project is to conduct a phase II, open-label, multi-center clinical trial evaluating the safety and efficacy of RVU120 in combination therapy with venetoclax in patients with AML or HR-MDS who have failed previous therapy with venetoclax and a hypomethylating agent.

RVU120 is a selective, first-in-class dual CDK8/CDK19 inhibitor. RVU120 has demonstrated efficacy in numerous in vitro and in vivo models of solid tumors as well as haematological malignancies. In addition, RVU120 showed early signs of clinical activity in treated patients. Two dose-escalation phase RVU120 clinical trials are currently ongoing in patients: (i) AML/HR-MDS and (ii) solid tumors.


Ryvu Therapeutics was founded in 2007 (as Selvita). It is a Polish biotechnology company developing innovative small molecule compounds with therapeutic potential in oncology. Ryvu Therapeutics is listed on the main market of the Warsaw Stock Exchange; is included in the sWIG80 index.


Our privacy policy